A Phase 4 interventional study of Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin in Coronary Artery Disease, sponsored by Samsung Medical Center. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one has the largest planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 4, reaches primary completion later than 6 of the 13 other live ones, and was the 15th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,500 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 520 across the 21 interventional studies, 16,487 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
3 of the studies in Coronary Artery Disease by Samsung Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT04014803Samsung Medical CenterAspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion | 2027-06-30 |
| NCT05221931Samsung Medical CenterDrug-Coated Balloon in Patients With High Bleeding Risk | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, open label, two-arm, randomized multicenter trial to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective percutaneous coronary intervention with drug eluting stents for complex coronary lesions.
Over the past several decades, dual antiplatelet therapy (DAPT) with the combination of aspirin and a P2Y12 inhibitor has become an essential treatment in patients undergoing percutaneous coronary intervention (PCI) to reduce ischemic events. Although the optimal duration of DAPT still remains controversial in patients with coronary artery disease, the recommended duration of maintenance of DAPT for patients undergoing PCI with drug-eluting stent is ≥12 months for those with acute coronary syndrome (ACS), and ≥6 months for those with stable coronary artery disease according to the current guidelines. However, individualized approach based on ischemic versus bleeding risks assessment is needed to determine the optimal duration of DAPT in various population.
Several studies reported that patients undergoing PCI for complex lesions had significantly higher rates of ischemic events than those with non-complex lesions. Moreover, prolonged DAPT of aspirin and clopidogrel more than 1 year significantly reduced the risk of cardiac ischemic events up to 44% in patients undergoing PCI for complex coronary lesions, and the current guideline recommends prolonged DAPT duration may be considered in patients undergoing complex PCI. Apart from prolonged use of DAPT, use of more potent P2Y12 inhibitor than clopidogrel may be another strategy to reduce ischemic events in patients undergoing PCI for complex coronary lesions. Prasugrel, a new thienopyridine, inhibits platelet aggregation more rapidly and potently than clopidogrel. In the TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel) study, prasugrel reduced ischemic events compared with clopidogrel in patients with acute coronary syndrome. Moreover, low dose prasugrel also reduced ischemic events without an excessive bleeding risk in Japanese population. Therefore, DAPT of aspirin and prasugrel would reduce recurrent ischemic events than DAPT of aspirin and clopidogrel in patients undergoing PCI for complex lesions, a high risk group of ischemic events, even when they do not present with myocardial infarction. So far, there have been no data on this issue.
The aim of the SMART-ATTEMPT (Aspirin and a PoTent P2Y12 inhibitor versus aspirin and clopidogrel Therapy in patients undergoing Elective percutaneous coronary intervention for coMPlex lesion Treatment) trial is to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective PCI for complex lesions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
③ Patients undergoing elective PCI as follows:
Exclusion Criteria:
⑩ Patients taking warfarin or novel oral anticoagulants (dabigatran, rivaroxaban, edoxaban, or apixaban)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily\* will be given for one year. \* Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement.
Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin
Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.
Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin
Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion 1. Prasugrel plus Aspirin arm 2. Clopidogrel plus Aspirin arm
Also known as: Prasugrel plus Aspirin or Clopidogrel plus Aspirin
Major adverse cardiac events (MACE)
A composite of death, myocardial infarction, or stent thrombosis
Time frame: 1-year after randomization
All-cause death
Death by any cause
Time frame: 1-year after randomization
Cardiac death
Death by cardiac cause
Time frame: 1-year after randomization
Myocardial infarction
Myocardial infarction
Time frame: 1-year after randomization
Stent thrombosis
Definite or probable stent thrombosis
Time frame: 1-year after randomization
Target lesion revascularization
Repeat revascularization for target lesion of index PCI
Time frame: 1-year after randomization
Target vessel revascularization
Repeat revascularization for target vessel of index PCI
Time frame: 1-year after randomization
Any revascularization
Any repeat revascularization
Time frame: 1-year after randomization
A composite of all-cause death/myocardial infarction/stent thrombosis/any revascularization
A composite of all-cause death/myocardial infarction/stent thrombosis/any revascularization
Time frame: 1-year after randomization
A composite of all-cause death/myocardial infarction
A composite of all-cause death/myocardial infarction
Time frame: 1-year after randomization
A composite of cardiac death/myocardial infarction
A composite of cardiac death/myocardial infarction
Time frame: 1-year after randomization
Cerebrovascular accident
Cerebrovascular accident
Time frame: 1-year after randomization
A composite of all-cause death/myocardial infarction/cerebrovascular accident
A composite of all-cause death/myocardial infarction/cerebrovascular accident
Time frame: 1-year after randomization
A composite of cardiac death/myocardial infarction/cerebrovascular accident
A composite of cardiac death/myocardial infarction/cerebrovascular accident
Time frame: 1-year after randomization
A composite of cardiac death/myocardial infarction/stent thrombosis
A composite of cardiac death/myocardial infarction/stent thrombosis
Time frame: 1-year after randomization
Bleeding by BARC types 3 or 5
Bleeding defined by Bleeding Academic Research Consortium (BARC) types 3 or 5
Time frame: 1-year after randomization
Bleeding by BARC types 2, 3, or 5
Bleeding defined by BARC types 2, 3 or 5
Time frame: 1-year after randomization
Net adverse clinical events
MACE + bleeding by BARC types 3 or 5
Time frame: 1-year after randomization
Started Jan 2020 (actual). Primary completion is estimated for Jun 2027, 89 months after the start.
Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 89 months is above that.
Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.